Has Jeffrey Deygoo, MD received payments from drug or device companies?

Yes. Drug and device makers reported $10,767 in general payments to Jeffrey Deygoo, MD across 135 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jeffrey Deygoo, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jeffrey Deygoo, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jeffrey Deygoo, MD

Interventional Pain Medicine · New York, NYNPI 1275920720

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,274 of the $10,767 with a category attached, or 67.6%. 16 manufacturers reported payments, led by Abbott at 26.5% of the total. Reporting peaked in 2022 at $5,063 and has fallen 96.9% since, to $159 in 2025.

$10,767in general payments, 2019–2025

Across 135 payments — averaging $79.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$3K
Boston Scientific$3K
Medtronic$2K
Relievant Medsystems, Inc.$1K
Vertos Medical, Inc.$626
Biotronik NRO, Inc.$302
plus $1K from 10 others

What the payments were for

Grants$751%
Travel & lodging$3,38231%
Food & beverage$7,27468%
Education$360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	53	$2,856
Boston Scientific	23	$2,723
Medtronic(2 entities)	18	$1,935
Relievant Medsystems, Inc.	10	$1,105
Vertos Medical, Inc.	7	$626
Biotronik NRO, Inc.	4	$302
Nalu Medical, Inc.	3	$297
Nevro Corp.	3	$154
Stryker	2	$145
MML US, Inc.	3	$140
Saluda Medical Americas, Inc.	2	$136
Painteq LLC	1	$114
Curonix LLC	1	$100
Tactile Systems Technology Inc	3	$81
Si-bone, Inc.	1	$29
Bioventus LLC	1	$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Intracept$2,105
Superion Indirect Decompression System$1,710
VenaSeal$1,224
mild Device Kit$564
Proclaim IPG$514
PROCLAIM$464
Nalu Neurostimulation System$267
Prospera$254
Octrode SCS Leads$140
GENERAL PAIN MANAGEMENT$130
Evoke SCS$117
INTELLIS$114
PAINTEQ$114
ReActiv8$112
SPECTRA WAVEWRITER$110
SPINEJACK$104

How this compares

$10,767 in reported general payments places this provider in the 75th percentile of 132 interventional pain medicine providers in New York.

See all interventional pain medicine providers in New York →

Medicare billing

Part B allowed, 2024

$348,113

Medicare patients

280

Services billed

15,952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Diclofenac Sodium	45	$3,035
Etodolac	45	$1,193
Tizanidine Hcl	23	$199
Methylprednisolone	38	$194
Cyclobenzaprine Hcl	16	$178
Gabapentin	24	$140
Pregabalin	21	$99
Meloxicam	17	$64

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in New York

Corey HunterNew York$446K
Neel MehtaNew York$432K
Kimberly SackheimNew York$102K
Suelane OuroNew York$68K
Gerard DegregorisNew York$49K
Marco PappagalloNew York$36K
Jason SieffermanNew York$29K
Barthelemy LiabaudNew York$20K
Devi NampiaparampilNew York$18K
Imran PunekarNew York$9K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →